vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and Workhorse Group Inc. (WKHS). Click either name above to swap in a different company.

Workhorse Group Inc. is the larger business by last-quarter revenue ($12.5M vs $11.0M, roughly 1.1× C4 Therapeutics, Inc.). Workhorse Group Inc. runs the higher net margin — -166.5% vs -186.0%, a 19.5% gap on every dollar of revenue. On growth, Workhorse Group Inc. posted the faster year-over-year revenue change (432.0% vs 112.8%). Over the past eight quarters, Workhorse Group Inc.'s revenue compounded faster (205.7% CAGR vs 90.4%).

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

Workhorse Group is an original equipment manufacturer and technology company headquartered in Sharonville, Ohio, USA. In 2025, it merged its operations with those of Motiv Electric Trucks, forming a new entity known as Workhorse.

CCCC vs WKHS — Head-to-Head

Bigger by revenue
WKHS
WKHS
1.1× larger
WKHS
$12.5M
$11.0M
CCCC
Growing faster (revenue YoY)
WKHS
WKHS
+319.2% gap
WKHS
432.0%
112.8%
CCCC
Higher net margin
WKHS
WKHS
19.5% more per $
WKHS
-166.5%
-186.0%
CCCC
Faster 2-yr revenue CAGR
WKHS
WKHS
Annualised
WKHS
205.7%
90.4%
CCCC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CCCC
CCCC
WKHS
WKHS
Revenue
$11.0M
$12.5M
Net Profit
$-20.5M
$-20.8M
Gross Margin
80.4%
Operating Margin
-210.1%
-28.6%
Net Margin
-186.0%
-166.5%
Revenue YoY
112.8%
432.0%
Net Profit YoY
40.7%
-171.8%
EPS (diluted)
$-0.09
$0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
WKHS
WKHS
Q4 25
$11.0M
$12.5M
Q3 25
$11.2M
$2.4M
Q2 25
$6.5M
$5.7M
Q1 25
$7.2M
$640.9K
Q4 24
$5.2M
$2.4M
Q3 24
$15.4M
$2.5M
Q2 24
$12.0M
$842.4K
Q1 24
$3.0M
$1.3M
Net Profit
CCCC
CCCC
WKHS
WKHS
Q4 25
$-20.5M
$-20.8M
Q3 25
$-32.2M
$-7.8M
Q2 25
$-26.0M
$-14.8M
Q1 25
$-26.3M
$-20.6M
Q4 24
$-34.6M
$29.0M
Q3 24
$-24.7M
$-25.1M
Q2 24
$-17.7M
$-26.3M
Q1 24
$-28.4M
$-29.2M
Gross Margin
CCCC
CCCC
WKHS
WKHS
Q4 25
80.4%
Q3 25
-323.2%
Q2 25
-130.2%
Q1 25
Q4 24
Q3 24
-164.7%
Q2 24
Q1 24
Operating Margin
CCCC
CCCC
WKHS
WKHS
Q4 25
-210.1%
-28.6%
Q3 25
-306.4%
-694.2%
Q2 25
-441.0%
-255.3%
Q1 25
-402.9%
-2002.9%
Q4 24
-728.4%
Q3 24
-183.9%
-564.5%
Q2 24
-178.6%
-2435.6%
Q1 24
-1060.2%
-1771.6%
Net Margin
CCCC
CCCC
WKHS
WKHS
Q4 25
-186.0%
-166.5%
Q3 25
-286.4%
-328.2%
Q2 25
-402.6%
-260.7%
Q1 25
-363.7%
-3221.0%
Q4 24
-667.8%
1233.7%
Q3 24
-160.6%
-1001.5%
Q2 24
-147.6%
-3124.3%
Q1 24
-933.2%
-2177.0%
EPS (diluted)
CCCC
CCCC
WKHS
WKHS
Q4 25
$-0.09
$0.09
Q3 25
$-0.44
$-0.50
Q2 25
$-0.37
$-1.67
Q1 25
$-0.37
$-4.68
Q4 24
$-0.50
$51.11
Q3 24
$-0.35
$-0.98
Q2 24
$-0.26
$-17.45
Q1 24
$-0.41
$-24.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
WKHS
WKHS
Cash + ST InvestmentsLiquidity on hand
$74.6M
$12.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$256.6M
$43.0M
Total Assets
$359.1M
$117.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
WKHS
WKHS
Q4 25
$74.6M
$12.9M
Q3 25
$58.8M
$12.7M
Q2 25
$78.2M
$2.2M
Q1 25
$51.3M
$2.6M
Q4 24
$55.5M
$6.6M
Q3 24
$59.6M
$3.2M
Q2 24
$73.1M
$5.3M
Q1 24
$89.7M
$6.7M
Stockholders' Equity
CCCC
CCCC
WKHS
WKHS
Q4 25
$256.6M
$43.0M
Q3 25
$154.4M
$32.1M
Q2 25
$174.1M
$22.3M
Q1 25
$195.1M
$31.4M
Q4 24
$216.0M
$-40.8M
Q3 24
$242.7M
$47.3M
Q2 24
$247.1M
$58.6M
Q1 24
$258.3M
$67.4M
Total Assets
CCCC
CCCC
WKHS
WKHS
Q4 25
$359.1M
$117.9M
Q3 25
$265.5M
$116.7M
Q2 25
$296.5M
$99.3M
Q1 25
$319.5M
$115.5M
Q4 24
$349.6M
$37.4M
Q3 24
$376.1M
$101.4M
Q2 24
$381.1M
$105.4M
Q1 24
$398.4M
$113.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
WKHS
WKHS
Operating Cash FlowLast quarter
$-22.1M
$-10.5M
Free Cash FlowOCF − Capex
$-11.1M
FCF MarginFCF / Revenue
-89.0%
Capex IntensityCapex / Revenue
4.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
WKHS
WKHS
Q4 25
$-22.1M
$-10.5M
Q3 25
$-31.2M
Q2 25
$-12.1M
Q1 25
$-33.3M
$-8.2M
Q4 24
$-17.9M
$2.0M
Q3 24
$-24.1M
Q2 24
$-5.0M
$-12.1M
Q1 24
$-18.1M
$-18.0M
Free Cash Flow
CCCC
CCCC
WKHS
WKHS
Q4 25
$-11.1M
Q3 25
$-31.6M
Q2 25
Q1 25
$-8.2M
Q4 24
$-17.9M
$1.2M
Q3 24
$-24.1M
Q2 24
$-5.2M
$-12.8M
Q1 24
$-21.0M
FCF Margin
CCCC
CCCC
WKHS
WKHS
Q4 25
-89.0%
Q3 25
-281.5%
Q2 25
Q1 25
-1275.0%
Q4 24
-346.5%
52.2%
Q3 24
-157.2%
Q2 24
-43.1%
-1523.4%
Q1 24
-1567.2%
Capex Intensity
CCCC
CCCC
WKHS
WKHS
Q4 25
4.8%
Q3 25
3.7%
Q2 25
Q1 25
2.8%
Q4 24
0.1%
31.2%
Q3 24
0.1%
Q2 24
1.6%
87.1%
Q1 24
0.0%
225.9%
Cash Conversion
CCCC
CCCC
WKHS
WKHS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.07×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons